MARKET

ESPR

ESPR

Esperion Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.60
+0.72
+2.58%
Opening 13:02 02/24 EST
OPEN
29.15
PREV CLOSE
27.88
HIGH
30.27
LOW
27.60
VOLUME
382.67K
TURNOVER
--
52 WEEK HIGH
67.59
52 WEEK LOW
23.90
MARKET CAP
797.27M
P/E (TTM)
-7.4137
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DJ Esperion Therapeutics Price Target Cut to $134.00/Share From $150.00 by Needham
Dow Jones · 7h ago
DJ Esperion Therapeutics Is Maintained at Strong Buy by Needham
Dow Jones · 7h ago
--Analyst Actions: Needham Adjusts Price Target on Esperion Therapeutics to $134 From $150, Maintains Strong Buy Rating
MT Newswires · 8h ago
DJ Esperion Therapeutics, Inc. CEO Timothy Mayleben on Q4 2020 Results -- Earnings Call Transcript >ESPR
Dow Jones · 14h ago
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
Zacks.com · 19h ago
Esperion Therapeutics EPS misses by $0.16, misses on revenue
Esperion Therapeutics (ESPR): Q4 GAAP EPS of -$3.89 misses by $0.16.Revenue of $9.64M (+883.7% Y/Y) misses by $2.88M.As of Dec. 31, 2020, cash, equivalents and investment securities available-for-sale totaled $305M.2021
Seekingalpha · 20h ago
Esperion Therapeutics Q4 EPS $(3.89) Misses $(3.76) Estimate, Sales $9.64M Miss $12.52M Estimate
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(3.89) per share which missed the analyst consensus estimate of $(3.76) by 3.46 percent. This is a 72.12 percent decrease over losses of $(2.26) per share
Benzinga · 20h ago
Esperion Therapeutics: R&D Expenses for the Full Yr 2021 Are Expected to Be $120 M to $130 M >ESPR
Esperion Therapeutics: R&D Expenses for the Full Yr 2021 Are Expected to Be $120 M to $130 M >ESPR
Dow Jones · 21h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ESPR. Analyze the recent business situations of Esperion Thera through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ESPR stock price target is 72.50 with a high estimate of 191.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 285
Institutional Holdings: 37.36M
% Owned: 134.03%
Shares Outstanding: 27.88M
TypeInstitutionsShares
Increased
50
4.39M
New
38
-1.10M
Decreased
50
4.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.48%
Pharmaceuticals & Medical Research
+1.39%
Key Executives
President/Chief Executive Officer/Director
Timothy Mayleben
Chief Financial Officer
Richard Bartram
Chief Operating Officer
Sheldon Koenig
Other
Ashley Hall
Lead Director/Independent Director
Nicole Vitullo
Director
Jeffrey Berkowitz
Independent Director
Alan Fuhrman
Independent Director
Antonio Gotto
Independent Director
Daniel Janney
Independent Director
Mark McGovern
Independent Director
Jay Shepard
Independent Director
Tracy Woody
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ESPR
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy.

Webull offers kinds of Esperion Therapeutics Inc stock information, including NASDAQ:ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.